RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effect...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Case Rep Oncol
Auteurs principaux: Carter, Corey A., Oronsky, Bryan T., Caroen, Scott Z., Scicinski, Jan J., Degesys, Aiste, Kim, Michelle M., Oronsky, Arnold L., Lybeck, Harry, Cabrales, Pedro, Oronsky, Neil, Reid, Tony, Roswarski, Joseph, Brzezniak, Christina
Format: Artigo
Langue:Inglês
Publié: S. Karger AG 2016
Sujets:
Published online: March, 2016
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4821137/
https://ncbi.nlm.nih.gov/pubmed/27065849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000444631
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires